Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings
- PMID: 21319198
- PMCID: PMC3079483
- DOI: 10.1002/hep.24127
Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings
Abstract
The diagnosis of nonalcoholic steatohepatitis (NASH) is defined by the presence and pattern of specific histological abnormalities on liver biopsy. A separate system of scoring the features of nonalcoholic fatty liver disease (NAFLD) called the NAFLD Activity Score (NAS) was developed as a tool to measure changes in NAFLD during therapeutic trials. However, some studies have used threshold values of the NAS, specifically NAS ≥5, as a surrogate for the histologic diagnosis of NASH. To evaluate whether this unintended use of the NAS is valid, biopsy and clinical data from the 976 adults in NASH Clinical Research Network (CRN) studies were reviewed. Biopsies were evaluated centrally by the NASH CRN Pathology Committee. Definite steatohepatitis (SH) was diagnosed in 58.1%, borderline SH in 19.5% and "not SH" in 22%. The NAS was ≥5 in 50% and ≤4 in 49%; in this cohort only 75% of biopsies with definite SH had an NAS ≥5, whereas 28% of borderline SH and 7% of "not SH" biopsies had NAS ≥5. Of biopsies with an NAS ≥5, 86% had SH and 3% "not SH". NAS ≤4 did not indicate benign histology; 29% had SH and only 42% had "not SH." Higher values of the NAS were associated with higher levels of alanine aminotransferase and aspartate aminotransferase, whereas the diagnosis of SH was associated with features of the metabolic syndrome.
Conclusion: The diagnosis of definite SH or the absence of SH based on evaluation of patterns as well as individual lesions on liver biopsies does not always correlate with threshold values of the semiquantitative NAS. Clinical trials and observational studies should take these different performance characteristics into account.
Copyright © 2010 American Association for the Study of Liver Diseases.
Figures



Comment in
-
Nonalcoholic fatty liver disease activity score and Brunt's pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: what do they mean and do they agree?Hepatology. 2011 Jun;53(6):2142-3; author reply 2143. doi: 10.1002/hep.24322. Hepatology. 2011. PMID: 21618266 No abstract available.
References
-
- Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–1321. - PubMed
-
- Brunt EM. Nonalcoholic steatohepatitis: Definition and pathology. Seminars in Liver Disease. 2001;21(1):3–16. - PubMed
-
- Panel. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA. 2001;285:2486–2497. - PubMed
-
- Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294(1):E15–E26. - PubMed
-
- Eeuschwander-Tetri BA. Fatty liver and the metabolic syndrome. Current Opinions in Gastroenterology. 2007;23:193–198. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UL1RR02501401/RR/NCRR NIH HHS/United States
- U01DK061713/DK/NIDDK NIH HHS/United States
- U01DK061731/DK/NIDDK NIH HHS/United States
- U01DK061737/DK/NIDDK NIH HHS/United States
- U01DK061718/DK/NIDDK NIH HHS/United States
- U01DK061728/DK/NIDDK NIH HHS/United States
- U01 DK061730/DK/NIDDK NIH HHS/United States
- U01 DK061728/DK/NIDDK NIH HHS/United States
- M01 RR000065/RR/NCRR NIH HHS/United States
- U01 DK061734/DK/NIDDK NIH HHS/United States
- M01RR020359/RR/NCRR NIH HHS/United States
- M01RR000827/RR/NCRR NIH HHS/United States
- U01DK061738/DK/NIDDK NIH HHS/United States
- U01 DK061737/DK/NIDDK NIH HHS/United States
- U01 DK061713/DK/NIDDK NIH HHS/United States
- UL1 RR024989/RR/NCRR NIH HHS/United States
- U01 DK061732/DK/NIDDK NIH HHS/United States
- UL1RR025741/RR/NCRR NIH HHS/United States
- U01 DK061731/DK/NIDDK NIH HHS/United States
- UL1RR02413101/RR/NCRR NIH HHS/United States
- U01 DK061718/DK/NIDDK NIH HHS/United States
- M01RR000065/RR/NCRR NIH HHS/United States
- M01 RR000188/RR/NCRR NIH HHS/United States
- P30 DK056341/DK/NIDDK NIH HHS/United States
- UL1 RR025741/RR/NCRR NIH HHS/United States
- U01DK061732/DK/NIDDK NIH HHS/United States
- M01 RR000750/RR/NCRR NIH HHS/United States
- U01 DK061738/DK/NIDDK NIH HHS/United States
- UL1RR024989/RR/NCRR NIH HHS/United States
- M01 RR000827/RR/NCRR NIH HHS/United States
- M01RR00188/RR/NCRR NIH HHS/United States
- U01DK061734/DK/NIDDK NIH HHS/United States
- U01DK061730/DK/NIDDK NIH HHS/United States
- M01 RR020359/RR/NCRR NIH HHS/United States
- M01RR000750/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous